Pages that link to "Q33173620"
Jump to navigation
Jump to search
The following pages link to Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. (Q33173620):
Displaying 50 items.
- Hypertrophic Cardiomyopathy in Childhood (Q24599577) (← links)
- Prediction of atrial fibrillation development and progression: Current perspectives (Q26750083) (← links)
- The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms (Q26823825) (← links)
- Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy (Q26999424) (← links)
- 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society (Q27341873) (← links)
- Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes (Q28248327) (← links)
- Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death (Q30478725) (← links)
- The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era. (Q31934960) (← links)
- Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy (Q33144725) (← links)
- Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management (Q33145671) (← links)
- Natural history of hypertrophic cardiomyopathy (Q33145751) (← links)
- Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. (Q33145986) (← links)
- Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy (Q33148488) (← links)
- Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration (Q33148719) (← links)
- Management of hypertrophic cardiomyopathy in children (Q33150554) (← links)
- Do myocardial perfusion SPECT and radionuclide angiography studies in adult patients with hypertrophic cardiomyopathy have prognostic implications? (Q33151899) (← links)
- Cardiac arrest and ventricular tachycardia in Japanese-type apical hypertrophic cardiomyopathy (Q33154004) (← links)
- Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers (Q33158326) (← links)
- Predictors of sudden cardiac death in hypertrophic cardiomyopathy (Q33175795) (← links)
- Percutaneous transluminal septal myocardial ablation (Q34027467) (← links)
- Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy (Q34028344) (← links)
- Coronary microvascular ischemia in hypertrophic cardiomyopathy - a pixel-wise quantitative cardiovascular magnetic resonance perfusion study (Q34091933) (← links)
- Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy (Q34140784) (← links)
- American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the Euro (Q34275552) (← links)
- Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population (Q35021932) (← links)
- Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. (Q35367410) (← links)
- Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy (Q35770817) (← links)
- The pathology of hypertrophic cardiomyopathy (Q35771667) (← links)
- Primary prophylaxis of sudden death in hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and dilated cardiomyopathy (Q36247394) (← links)
- Right Ventricular and Right Atrial Involvement Can Predict Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy? (Q36473784) (← links)
- Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). (Q36533003) (← links)
- Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration (Q36846107) (← links)
- The phenotype/genotype relation and the current status of genetic screening in hypertrophic cardiomyopathy, Marfan syndrome, and the long QT syndrome (Q36846820) (← links)
- Contemporary treatment of hypertrophic cardiomyopathy (Q37227838) (← links)
- Predictors of Atrial Fibrillation Risk in Hypertrophic Cardiomyopathy (Q37469007) (← links)
- Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy (Q37766182) (← links)
- Impact of Genetic Insights Into Mendelian Disease on Cardiovascular Clinical Practice (Q37837294) (← links)
- Interventional treatments for hypertrophic cardiomyopathy. (Q37925001) (← links)
- Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. (Q38135337) (← links)
- Sudden cardiac death in patients with nonischemic cardiomyopathy (Q38191069) (← links)
- Vitamin K antagonist use for all patients with hypertrophic cardiomyopathy and atrial fibrillation: analysis of the literature and guideline review (Q38206840) (← links)
- Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy (Q38436996) (← links)
- Incidence of ischemic stroke and systemic embolism in patients with hypertrophic cardiomyopathy, nonvalvular atrial fibrillation, CHA2DS2-VASc score of ≤1 and without anticoagulant therapy (Q40672562) (← links)
- Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial (Q41657513) (← links)
- Sudden cardiac arrest in apical hypertrophic cardiomyopathy (Q41906819) (← links)
- Hypertrophic cardiomyopathy in the Saudi Arabian population: Clinical and echocardiographic characteristics and outcome analysis (Q41981308) (← links)
- Outcomes in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a survival meta-analysis (Q42328745) (← links)
- Mutations in the β-Myosin Heavy Chain Gene in Southern Chinese Families with Hypertrophic Cardiomyopathy (Q42916648) (← links)
- Screening for hypertrophic cardiomyopathy in a young male military population (Q44386722) (← links)
- Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy (Q45233058) (← links)